Putin, Rouhani stress importance of joint efforts in settlement of Syrian conflictRussian Politics & Diplomacy May 27, 14:32
Federatsiya spacecraft’s first flight may be rescheduled to 2022 - sourceScience & Space May 27, 14:29
Zbigniew Brzezinski dies at age of 89World May 27, 6:57
More than two-thirds of Russians say would like to venerate St Nicholas’s relicsSociety & Culture May 27, 6:40
Russian space budget may grow this yearScience & Space May 26, 20:48
Moscow hopes London High Court will deliver judgement on Ukraine’s debt to Russia soonBusiness & Economy May 26, 20:21
Hungarian top diplomat: EU must discuss anti-Russian sanctionsWorld May 26, 19:56
Russian, French top diplomats discuss preparations for Putin’s visit to FranceRussian Politics & Diplomacy May 26, 19:47
Moscow comments on Tallinn’s move to expel Russian diplomatsRussian Politics & Diplomacy May 26, 19:43
BASEL, Switzerland and IRVINE, California, June 6, 2013 /PRNewswire/ -- University Children's Hospital Basel in Basel, Switzerland, and Masimo (NASDAQ: MASI) today announced that the hospital has become the first multi-department pediatric facility in Central Europe to install on all general ward beds Masimo Patient SafetyNet™, a remote monitoring and clinician notification system shown to keep patients safer, enabling a 65% reduction in rapid response team activations and 48% reduction in ICU transfers.
The installation at the University Children's Hospital Basel – Universitats-Kinderspital Beider Basel (UKBB) – took place after an extensive evaluation process resulting in the organization's standardization to Masimo SET® pulse oximetry.
"We are pleased about the improved monitoring quality for patients on all our general wards, covering 80 beds for inpatient care," Ruth Spalinger, Nurse Manager at UKBB said of Patient SafetyNet. "We have observed that it's especially beneficial for our most vulnerable patients, who potentially suffer from respiratory depression. And, our staff has been extremely satisfied with the system."
UKBB joins a growing list of prominent health systems around the world using Patient SafetyNet, which combines the performance of Masimo SET® pulse oximetry, the enabler of reliable monitoring in the general ward, with ventilation monitoring and wireless clinician notification. Patient SafetyNet can help ensure patients' safety by noninvasively and continuously measuring and tracking their underlying physiological conditions and changes that signal declining health status in real-time. When changes occur in the measured values, which may indicate deterioration in the patient's condition, the system automatically sends wireless alerts directly to clinicians – prompting a potentially lifesaving response to the patient's bedside. Patient SafetyNet has been clinically shown to reduce preventable and costly rescue events, transfers to intensive care units, and deaths related to opioid-induced respiratory depression.
"University Children's Hospital Basel has made the safety of their patients its first priority," said Joe Kiani, founder and CEO of Masimo. "We are thrilled to be partnering with this highly esteemed and modern healthcare facility to help protect young patients, improve outcomes, and reduce costs."
Experience." Anesthesia Patient Safety Foundation Newsletter Spring-Summer 2012. Available online
About University Children's Hospital Basel
As an independent university pediatric center, the Children's Hospital Basel offers full capabilities to care for seriously ill children. In a unique beautiful environment, services of many different pediatric subspecialties are offered for in- and out patients. The Children's Hospital Basel is a partner of the University of Basel and responsible for education and research related to the care of the full spectrum of pediatric patients. For more information, visit www.ukbb.ch/en/ukbb/the-hospital.html
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo SET® and Masimo rainbow® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions that all neonatal patients at University Children's Hospital Basel will be cared for using the most technologically and clinically-advanced noninvasive patient monitoring solutions available; risks related to our belief that Masimo Patient SafetyNet can help keep patients safer by noninvasively, continuously measuring and tracking their underlying physiological condition to help hospitals avoid preventable patient deaths and injuries associated with failure to rescue events, risks related to our assumptions of the repeatability of clinical results obtained, and risks related to the system's ability to significantly decrease traumatic critical events and costly ICU transfers to help improve patient outcomes and reduce costs; risks related to our belief that Masimo SET virtually eliminates false alarms and increases a clinician's ability to detect life-threatening events; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Sandra Soland or Martina Beranek, Universitats-Kinderspital Beider Basel (UKBB)
Mike Drummond, Masimo Corporation